GastrointestinalResearch Phase

Glucagon Receptor Antagonist Peptides

Subcutaneous injection

Overview

Glucagon receptor antagonist peptides are a class of molecules designed to block the glucagon receptor and prevent glucagon-mediated hepatic glucose output. These peptides typically consist of modified glucagon analogs with substitutions that convert agonist activity to antagonism.

Mechanism of Action

The therapeutic rationale focuses on lowering blood glucose in type 2 diabetes by reducing hepatic gluconeogenesis and glycogenolysis. Structural modifications also enhance metabolic stability and receptor selectivity..

Research Summary & Key Findings

Early clinical studies of peptide-based glucagon receptor antagonists demonstrated glucose-lowering efficacy but raised concerns about hepatic steatosis and increased LDL cholesterol. Development efforts have largely shifted to small molecule antagonists and monoclonal antibodies due to pharmacokinetic limitations of peptide scaffolds. Preclinical models continue to validate the glucagon receptor as a target for diabetes, though no peptide antagonist has advanced to late-stage trials.

Clinical Status

Research Phase

Glucagon Receptor Antagonist Peptides is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.

Administration Routes

Subcutaneous injection

Related Peptides in Gastrointestinal

Find a Provider

Find a verified provider who offers Glucagon Receptor Antagonist Peptides therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Glucagon Receptor Antagonist Peptides.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.